keyword
https://read.qxmd.com/read/38493239/beyond-the-marrow-insights-from-comprehensive-next-generation-sequencing-of-extramedullary-multiple-myeloma-tumors
#1
JOURNAL ARTICLE
T Jelinek, D Zihala, T Sevcikova, A Anilkumar Sithara, V Kapustova, H Sahinbegovic, O Venglar, L Muronova, L Broskevicova, S Nenarokov, D Bilek, T Popkova, H Plonkova, J Vrana, V Zidlik, P Hurnik, M Havel, M Hrdinka, Z Chyra, G Stracquadanio, M Simicek, R Hajek
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation sequencing analysis of EMM tumors (N = 14) to date, uncovering key molecular features and describing the tumor microenvironment. We observed the co-occurrence of 1q21 gain/amplification and MAPK pathway mutations in 79% of EMM samples, suggesting that these are crucial mutational events in EMM development. We also demonstrated that patients with mutated KRAS and 1q21 gain/amplification at the time of diagnosis have a significantly higher risk of EMM development (HR = 2...
March 16, 2024: Leukemia
https://read.qxmd.com/read/38481861/long-noncoding-rna-gprc5d-as1-in-renal-cell-carcinoma-a-molecular-mechanism-study
#2
JOURNAL ARTICLE
Mingfei Jia, Xi Chen, Shaosan Kang, Fenghong Cao, Yansheng Zhao, Liguo Zhang, Xinghua Bao, Lei Wang, Hengran Li, Chenggang Li
BACKGROUND: Clear cell renal cell carcinoma (RCC) is the most common subtype of RCC. Although targeted therapy can provide superior treatment outcomes, it is prone to drug resistance, and individual responses to immunotherapy vary greatly. Therefore, finding new diagnostic and therapeutic targets for RCC is of considerable importance. Long noncoding RNA (lncRNA) GPRC5D-AS1 can serve as a biomarker in clinical applications and the prognosis of lung squamous cell carcinoma. However, the specific mechanism of action of lncRNA GPRC5D-AS1 in RCC has not yet been clarified...
February 29, 2024: Translational Andrology and Urology
https://read.qxmd.com/read/38462921/the-impressive-efficacy-of-anti-g-protein-coupled-receptor-class-c-group-5-member-d-chimeric-antigen-receptor-t-cells-in-patients-with-relapsed-or-refractory-multiple-myeloma
#3
JOURNAL ARTICLE
https://read.qxmd.com/read/38448422/correction-gprc5d-as-a-novel-target-for-the-treatment-of-multiple-myeloma-a-narrative-review
#4
Paula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari
No abstract text is available yet for this article.
March 6, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38447541/peeling-back-the-layers-recurrent-talquetamab-skin-toxicity-after-supportive-stem-cell-boost-in-multiple-myeloma
#5
Alexander D Heini, Vera Ulrike Bacher, Dilara Akhoundova, Katja Seipel, Thomas Pabst
Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a supportive hematopoietic stem cell boost to treat persistent late cytopenias after CAR-T therapy...
March 6, 2024: Acta Haematologica
https://read.qxmd.com/read/38432433/characteristics-and-incidence-of-infections-in-patients-with-multiple-myeloma-treated-by-bispecific-antibodies-a-national-retrospective-study-on-the-behalf-of-g2i-and-ifm
#6
JOURNAL ARTICLE
Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau, Stéphanie Harel, Blandine Denis, Guillaume Escure, Emmanuel Faure, Simon Jamard, Francois Danion, Cécile Sonntag, Florence Ader, Lionel Karlin, Sarah Soueges, Clarisse Cazelles, Clémentine de La Porte des Vaux, Laurent Frenzel, Fanny Lanternier, Xavier Brousse, Titouan Cazaubiel, Pierre Berger, Aude Collignon, Mathieu Blot, Andrea Pieragostini, Morgane Charles, Carine Chaleteix, Alexis Redor, Virginie Roland, Tom Cartau, Margaret Macro, Thomas Chalopin, Nicolas Vallet, Aurore Perrot, Guillaume Martin-Blondel
OBJECTIVES: Bispecific antibodies (BsAbs) are an effective treatment used in relapsed/refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appeared to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors and outcomes of infections in patients treated with BsAb are still needed. METHODS: A retrospective, multicenter study in BsAb-treated MM patients was conducted in 14 French centers from December 2020 to February 2023...
March 1, 2024: Clinical Microbiology and Infection
https://read.qxmd.com/read/38429446/a-novel-t-cell-redirecting-anti-gprc5d%C3%A2-%C3%A3-%C3%A2-cd3-bispecific-antibody-with-potent-antitumor-activity-in-multiple-myeloma-preclinical-models
#7
JOURNAL ARTICLE
Urara Tomita, Yoko Ishimoto, Masaki Ri, Yumi Kawase, Yoshiyuki Hizukuri, Chikako Maru, Kayoko Nanai, Ryuichi Nakamura, Makiko Nakayama, Keiko Oguchi-Oshima, Hiroyuki Sumi, Toshiaki Ohtsuka, Shinsuke Iida, Toshinori Agatsuma
G-protein-coupled receptor class 5 member D (GPRC5D) is detected in malignant plasma cells in approximately 90% of patients diagnosed with multiple myeloma (MM). Here, we constructed BsAb5003, a novel humanized bispecific monoclonal antibody targeting CD3 and GPRC5D, and evaluated its therapeutic impact on MM. BsAb5003 induced specific cytotoxicity of GPRC5D-positive MM cells with concomitant T cell activation and cytokine release. The efficacy of BsAb5003 was associated with GPRC5D expression levels in MM cell lines...
March 1, 2024: Scientific Reports
https://read.qxmd.com/read/38426409/correction-defining-an-optimal-dual-targeted-car-t-cell-therapy-approach-simultaneously-targeting-bcma-and-gprc5d-to-prevent-bcma-escape-driven-relapse-in-multiple-myeloma
#8
(no author information available yet)
No abstract text is available yet for this article.
March 1, 2024: Blood cancer discovery
https://read.qxmd.com/read/38402374/comparative-efficacy-of-talquetamab-vs-current-treatments-in-the-locommotion-and-momment-studies-in-patients-with-triple-class-exposed-relapsed-refractory-multiple-myeloma
#9
JOURNAL ARTICLE
Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W C J van de Donk, Enrique M Ocio, Joaquin Martinez-Lopez, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imene Haddad, Thomas Renaud, Eric Ammann, Jedelyn Cabrieto, Nolen Perualila, Ryan Gan, Youyi Zhang, Trilok Parekh, Claire Albrecht, Katja Weisel, Maria-Victoria Mateos
INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons. METHODS: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0...
February 24, 2024: Advances in Therapy
https://read.qxmd.com/read/38307865/gprc5d-as-a-novel-target-for-the-treatment-of-multiple-myeloma-a-narrative-review
#10
REVIEW
Paula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari
Multiple myeloma is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Despite advances in therapy, patients experience cycles of remission and relapse, with each successive line of therapy associated with poorer outcomes; therefore, therapies with different mechanisms of action against new myeloma antigens are needed. G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a novel therapeutic target for the treatment of multiple myeloma. We review the biology and target validation of GPRC5D, and clinical data from early phase trials of GPRC5D-targeting bispecific antibodies, talquetamab and forimtamig, and chimeric antigen receptor T cell (CAR-T) therapies, MCARH109, OriCAR-017, and BMS-986393...
February 2, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38194680/bcma-or-gprc5d-targeting-bispecific-antibodies-in-multiple-myeloma-efficacy-safety-and-resistance-mechanisms
#11
JOURNAL ARTICLE
Holly Lee, Paola Neri, Nizar J Bahlis
Bispecific antibodies that engage T cells to target B cell maturation antigen (BCMA) or G protein-coupled receptor class C group 5 member D (GPRC5D) have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory MM leading to the recent accelerated approval of teclistamab, elranatamab and talquetamab by health agencies. Future challenges however remain to define their optimal dosing schedule and duration, sequencing and integration with established anti-MM therapeutics as well as delineating the biological and clinical mediators of immune escape...
January 9, 2024: Blood
https://read.qxmd.com/read/38183209/recent-advances-and-future-perspectives-of-t-cell-engagers-in-lymphoid-malignancies
#12
JOURNAL ARTICLE
Yuko Shirouchi, Dai Maruyama
Bispecific antibodies (BsAbs) are monoclonal antibodies that simultaneously bind to a specific antigen on tumors and CD3 on T cells, leading to T cell activation and subsequent tumor cell lysis. Several CD20 × CD3 BsAbs are being developed for B-cell lymphomas. Furthermore, multiple clinical trials to evaluate BsAbs for the treatment of multiple myeloma, with targets including BCMA, GPRC5D and FcRH5, are ongoing. Emerging evidence suggests promising efficacy in heavily pretreated patients with relapsed or refractory lymphoid malignancies, showing an overall response rate of 50-60%, with complete response rates of 30-40% for relapsed or refractory large B-cell lymphoma and 60-70% for relapsed or refractory multiple myeloma...
January 5, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38136320/br109-a-novel-fully-humanized-t-cell-engaging-bispecific-antibody-with-gprc5d-binding-has-potent-antitumor-activities-in-multiple-myeloma
#13
JOURNAL ARTICLE
Ying Liu, Ya-Qiong Zhou, Lei Nie, Shan-Shan Zhu, Na Li, Zhen-Hua Wu, Qi Wang, Jian Qi, Bing-Yuan Wu, Shu-Qing Chen, Hai-Bin Wang
At present, multiple myeloma (MM) is still an essentially incurable hematologic malignancy. Although BCMA-targeted therapies have achieved remarkable results, BCMA levels were found to be downregulated in patients with MM who relapsed after these treatments. Therefore, the search for other antigens specific to MM has become a priority. Independently of BCMA expression, G-protein-coupled receptor family C group 5 member D (GPRC5D) is mainly expressed in the plasma cells of MM patients, while it is expressed in a limited number of normal tissues...
December 9, 2023: Cancers
https://read.qxmd.com/read/38100482/lncrna-gprc5d-as1-as-a-cerna-inhibits-skeletal-muscle-aging-by-regulating-mir-520d-5p
#14
JOURNAL ARTICLE
Miao Yu, Xiuting He, Ting Liu, Jie Li
Sarcopenia induced by muscle aging is associated with negative outcomes in a variety of diseases. Long non-coding RNAs are a class of RNAs longer than 200 nucleotides with lower protein coding potential. An increasing number of studies have shown that lncRNAs play a vital role in skeletal muscle development. According to our previous research, lncRNA GPRC5D-AS1 is selected in the present study as the target gene to further study its effect on skeletal muscle aging in a dexamethasone-induced human muscle atrophy cell model...
December 9, 2023: Aging
https://read.qxmd.com/read/38099401/update-on-the-current-and-future-use-of-car-t-to-treat-multiple-myeloma
#15
REVIEW
Zhubin Gahvari, Matthew Brunner, Timothy Schmidt, Natalie S Callander
Chimeric antigen receptor T-cell (CAR-T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B-cell maturation antigen (BCMA) is the most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing expression of this essential transmembrane protein on malignant plasma cells as patients develop more advanced disease. This review will explore the earliest CAR-T trials in myeloma, discuss important issues involved in CAR-T manufacturing and processing, as well as review current clinical trials that led to the approval of the two commercially available CAR-T products, Idecabtagene vicleucel and ciltacabtagene autoleucel...
December 15, 2023: European Journal of Haematology
https://read.qxmd.com/read/38092979/characterization-of-dysgeusia-and-xerostomia-in-patients-with-multiple-myeloma-treated-with-the-t-cell-redirecting-gprc5d-bispecific-antibody-talquetamab
#16
JOURNAL ARTICLE
A M G A Laheij, N W C J van de Donk
PURPOSE: In recent years, various immunotherapies have improved the survival of patients with multiple myeloma (MM). However, there remains an unmet need for novel agents. Talquetamab is the first-in-class GPRC5D-targeting T-cell redirecting bispecific antibody, which has substantial activity in advanced MM. Rapidly after the start of talquetamab treatment, patients reported taste changes (dysgeusia; 60% of patients), and a feeling of dry mouth (xerostomia; 30-57% of patients), which may be related to expression of the target antigen in healthy tissues, such as taste buds...
December 14, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38081142/integrating-immune-therapies-for-the-treatment-of-multiple-myeloma
#17
REVIEW
Lekha Mikkilineni, Surbhi Sidana
Patients with relapsed or refractory multiple myeloma (RRMM) that is refractory to a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody (triple-class refractory MM) have poor outcomes. Recently, 2 classes of T-cell engaging therapies-CAR T-cell therapy and bispecific T-cell engaging antibodies (BsAbs)-have resulted in unprecedented response rates and survival outcomes in these heavily pretreated patients. The most common targets are BCMA and GPRC5D, with other targets in development...
December 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38066842/current-use-of-bispecific-antibodies-to-treat-multiple-myeloma
#18
JOURNAL ARTICLE
Holly Lee, Paola Neri, Nizar J Bahlis
Targeted immunotherapy has significantly improved the outcome of patients with hematological malignancies by leveraging the power of the immune system to eliminate tumor cells. In multiple myeloma (MM), bispecific T-cell engagers (BsAb) targeting B-cell maturation antigen (BCMA), G protein-coupled receptor, class C, group 5, member D (GPRC5D), and Fc receptor-like 5 (FcRL5) have already demonstrated remarkable clinical activity in triple-class refractory patients. However, responses to BsAb are not universal, and resistance often emerges while on therapy...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/38035078/rna-sequencing-based-first-choice-of-treatment-and-determination-of-risk-in-multiple-myeloma
#19
JOURNAL ARTICLE
Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose
BACKGROUND: Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk assessment is advisable as patient's life expectancy varies between months and decades. METHODS: We first assess feasibility of RNA-sequencing in a multicenter trial (GMMG-MM5, n=604 patients)...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37924369/beyond-bcma-why-gprc5d-could-be-the-right-way-treatment-strategies-with-immunotherapy-at-relapse-after-anti-bcma-agents
#20
REVIEW
Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Multiple Myeloma remains incurable, and there is a need for therapies with novel mechanisms of action. Recently, B cell maturation antigen targeted therapy has demonstrated deep and durable responses in a largely treated population. However, the relapse rate of myeloma patients after anti-BCMA treatment strategies is increasing worldwide, and one of the most challenging issues for them is to choose the best therapy sequencing. After anti-BCMA treatment, retreatment with anti-BCMA drugs remains an option, but new targets are emerging strongly...
November 4, 2023: Cancer Immunology, Immunotherapy: CII
keyword
keyword
170442
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.